- Home
- INZY vs SMHI Comparison
INZY vs SMHI Comparison
Compare INZY & SMHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- SMHI
- Stock Information
- Founded
- INZY 2015
- SMHI 1989
- Country
- INZY United States
- SMHI United States
- Employees
- INZY N/A
- SMHI N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- SMHI Marine Transportation
- Sector
- INZY Health Care
- SMHI Consumer Discretionary
- Exchange
- INZY Nasdaq
- SMHI Nasdaq
- Market Cap
- INZY 188.2M
- SMHI 189.9M
- IPO Year
- INZY 2020
- SMHI N/A
- Fundamental
- Price
- INZY $1.60
- SMHI $6.95
- Analyst Decision
- INZY Strong Buy
- SMHI
- Analyst Count
- INZY 8
- SMHI 0
- Target Price
- INZY $17.75
- SMHI N/A
- AVG Volume (30 Days)
- INZY 666.9K
- SMHI 184.7K
- Earning Date
- INZY 11-05-2024
- SMHI 02-27-2025
- Dividend Yield
- INZY N/A
- SMHI N/A
- EPS Growth
- INZY N/A
- SMHI N/A
- EPS
- INZY N/A
- SMHI N/A
- Revenue
- INZY N/A
- SMHI $274,636,000.00
- Revenue This Year
- INZY N/A
- SMHI $6.04
- Revenue Next Year
- INZY N/A
- SMHI $11.18
- P/E Ratio
- INZY N/A
- SMHI N/A
- Revenue Growth
- INZY N/A
- SMHI 3.89
- 52 Week Low
- INZY $1.62
- SMHI $5.80
- 52 Week High
- INZY $7.80
- SMHI $15.36
- Technical
- Relative Strength Index (RSI)
- INZY 22.68
- SMHI 59.11
- Support Level
- INZY $2.68
- SMHI $6.63
- Resistance Level
- INZY $3.18
- SMHI $7.23
- Average True Range (ATR)
- INZY 0.27
- SMHI 0.29
- MACD
- INZY -0.11
- SMHI 0.10
- Stochastic Oscillator
- INZY 1.87
- SMHI 90.91
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides world-wide marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations including wind farms; handle anchors and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico); Africa and Europe; Middle East and Asia and Latin America.